Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Throughout the last three months, 7 analysts have evaluated Inspire Medical Systems (NYSE:INSP), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 1 | 4 | 2 | 0 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 1 | 4 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 1 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $212.86, with a high estimate of $260.00 and a low estimate of $170.00. Highlighting a 10.51% decrease, the current average has fallen from the previous average price target of $237.86.
A comprehensive examination of how financial experts perceive Inspire Medical Systems is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Mike Kratky | Leerink Partners | Raises | Market Perform | $197.00 | $167.00 |
Brett Fishbin | Keybanc | Lowers | Overweight | $236.00 | $278.00 |
Shagun Singh | RBC Capital | Maintains | Outperform | $260.00 | $260.00 |
Mike Polark | Baird | Lowers | Outperform | $200.00 | $220.00 |
Richard Newitter | Truist Securities | Lowers | Buy | $217.00 | $280.00 |
Kallum Titchmarsh | Morgan Stanley | Lowers | Overweight | $210.00 | $250.00 |
Jonathan Block | Stifel | Lowers | Hold | $170.00 | $210.00 |
For valuable insights into Inspire Medical Systems's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Inspire Medical Systems analyst ratings.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Inspire Medical Systems displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 29.65%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Inspire Medical Systems's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 5.0%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.6%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.38%, the company showcases effective utilization of assets.
Debt Management: Inspire Medical Systems's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: INSP